Microbiota – a key to healing the gastrointestinal tract?

Patrycja Szachta, Anna Bartnicka, Mirosława Gałęcka


At present, it is already known that many gastrointestinal tract diseases are caused by disorders of the intestinal ecosystem. The contribution of microbiota disorders to the development and sustaining of inϐlammatory bowel diseases, irritable bowel syndrome, necrotizing enterocolitis, constipation or bloating has been demonstrated in numerous scientiϐic studies. Another matter is bacterial imbalance in food allergy and atopic diseases. The effectiveness of probiotics and prebiotics in these diseases has been repeatedly conϐirmed, which made researchers search for new diseases in which probiotics could be an efϐicient therapeutic solution. Reports have also been published on microbiota disturbances in children with a spectrum of autistic disorders, depression or metabolic syndrome, and in obese patients. New micro -organisms have been discovered, which in addition to Lactobacillus or Biϔidobacterium bacteria, may signiϐicantly inϐluence the improvement of human health. Especially promising are two bacterial species, Akkermansia muciniphila and Faecalibacterium prausnitzii, which seem to interact in continuity regeneration of the intestinal epithelium. A. muciniphila has the ability to degrade mucin, while producing acetic acid, propionic acid and oligosaccharides. These products become the substrate for F. prausnitzii, one of the main producers of butyrate in the intestine. The anaerobic butyrate -producing bacterium helps to inhibit inϐlammation in the gastrointestinal tract, while preventing increased intestinal permeability. Growth stimulation in bacteria (e.g. towards prebiotic therapy) may therefore prove to be a valuable nutritional option and an efficient way to restore the intestinal epithelium. While A. muciniphila is extensively studied in the context of obesity and diabetes, F. prausnitzii may become an interesting marker for Crohn’s disease activity. The aim of this paper is to present new and promising aspects of intestinal microbiota restoration in the treatment of selected diseases.


Akkermansia muciniphila, Faecalibacterium prausnitzii, probiotics, prebiotics

Full Text:

PDF (Język Polski)


Hosono A. Fermented milk in the Orient. In: Nagasawa Y, Hosono A, editors. Functions of fermented milk: challenges for the health sciences. London:

Elsevier Applied Science; 1992. p. 61-78.

Shortt C. The probiotic century: historical and current perspectives, Trends Food Sci Technol 1999;10(12):411-7.

Brudziński J. O występowaniu bac. proteus vulgaris w stolcach niemowląt, próba leczenia przez podawanie hodowli bakteryjnych. Przegl Lek 1899;8:17.

Metchnikoff E, Chalmers Mitchell P. Nature of man or studies in optimistic philosophy. Whitefish: Kessinger Publishing; 1910.

Metchnikoff E, Chalmers Mitchell P. The prolongation of life: optimistic studies. New York: Springer Publishing Company; 2004.

Del Piano M, Morelli L, Strozzi GP, Allesina S, Barba M, Deidda F, et al. Probiotics: from research to consumer. Dig Liver Dis 2006;38(Suppl 2):248-55.

Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003; 361:512-9.

Soccol CR. The potential of probiotics. Food Technol Biotechnol 2010; 48(4):413-34.

van Immerseel F, Ducatelle R, de Vos M, Boon N, Van De Wiele T, Verbeke K, et al. Butyric acid-producing anaerobic bacteria as a novel probiotic treatment approach for inflammatory bowel disease. J Med Microbiol 2010;59(Pt 2):141-3.

Gałecka M, Szachta P, Bartnicka A, Łykowska -Szuber L, Eder P, Schwiertz A. Faecalibacterium prausnitzii and Crohn’s disease – is there any connection?

Pol J Microbiol 2013;62(1):91-5.

Schwiertz A, Jacobi M, Frick JS, Richter M, Rusch K. Microbiota in pediatric inflammatory bowel disease. J Pediatr 2010;157(2):240-4. doi: 10.1016/j. jpeds.2010.02.046. Epub 2010 Apr 18.

Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez -Humarán LG, Gratadoux JJ, et al. Faecalibacterium prausnitzii is an anti -inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 2008;105(43):16731-6.

Qiu X, Zhang M, Yang X, Hong N, Yu C. Faecalibacterium prausnitzii upregulates regulatory T cells and anti -inflammatory cytokines in treating TNBS -induced colitis. J Crohns Colitis 2013;7(11):e558-68. doi: 10.1016/j. crohns.2013.04.002. Epub 2013 May 2.

Martín R, Chain F, Miquel S, Lu J, Gratadoux JJ, Sokol H, et al. The commensal bacterium Faecalibacterium prausnitzii is protective in DNBS-induced chronic moderate and severe colitis models. Inflamm Bowel Dis 2014;20(3):417-30.

Flint HJ, Duncan SH, Scott KP, Louis P. Interactions and competition within the microbial community of the human colon: links between diet and health. Environ Microbiol 2007;9(5):1101-11.

Derrien M, Vaughan EE, Plugge CM, de Vos WM. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin -degrading bacterium. Int J Syst Evol Microbiol 2004;54(Pt 5):1469-76.

van Passel MW, Kant R, Zoetendal EG, Plugge CM, Derrien M, Malfatti SA, et al. The genome of Akkermansia muciniphila, a dedicated intestinal mucin degrader, and its use in exploring intestinal metagenomes. PLoS ONE 2011;6(3):e16876. doi: 10.1371/journal.pone.0016876.

Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, et al. Cross -talk between Akkermansia muciniphila and intestinal epithelium controls diet -induced obesity. Proc Natl Acad Sci U S A 2013; 110(22):9066-71.

Kang CS, Ban M, Choi EJ, Moon HG, Jeon JS, Kim DK, et al. Extracellularvesicles derived from gut microbiota, especially Akkermansia muciniphila, protect the progression of dextran sulfate sodium -induced colitis. PLoS One 2013;8(10):e76520.

Ganesh BP, Klopfleisch R, Loh G, Blaut M. Commensal Akkermansia muciniphila exacerbates gut inflammation in Salmonella Typhimurium-infected gnotobiotic mice. PLoS One 2013;8(9):e74963. doi: 10.1371/ journal.pone.0074963. eCollection 2013.

Muccioli GG, Naslain D, Bäckhed F, Reigstad CS, Lambert DM, Delzenne NM, et al. The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol 2010;6:392. doi: 10.1038/msb.2010.46.

Thomas LV, Ockhuizen T, Suzuki K. Exploring the influence of the gut microbiota and probiotics on health: a symposium report. Br J Nutr 2014;112(Suppl 1):1-18.

DOI: https://doi.org/10.21164/pomjlifesci.160

Copyright (c) 2016

License URL: https://creativecommons.org/licenses/by-nc-nd/3.0/pl/